Levicept’s LEVI-04 Shows Potential Disease-Modifying Effects in Osteoarthritis Phase II Trial
Event summary
- Levicept will present Phase II data at EULAR 2026 suggesting LEVI-04 may modify disease in osteoarthritis (OA) by reducing bone marrow lesions (BMLs).
- The study enrolled 518 participants with knee OA, showing dose-dependent reductions in BML presence and area compared to placebo.
- LEVI-04 demonstrated clinically meaningful improvements in pain and function, with outcomes at or above those for NSAIDs.
- Professor Philip Conaghan will compare joint safety outcomes of LEVI-04 with anti-NGF treatment fasinumab, highlighting differentiated mechanisms.
The big picture
Levicept’s Phase II data positions LEVI-04 as a potential first-in-class treatment for osteoarthritis, combining disease modification with analgesia. The results could reshape the competitive landscape for OA therapies, particularly against anti-NGF treatments like fasinumab. With backing from investors including Pfizer Ventures, Levicept is well-positioned to capitalize on the growing demand for safer, more effective OA treatments.
What we're watching
- Clinical Differentiation
- Whether LEVI-04’s disease-modifying potential and safety profile can position it as a leading OA treatment.
- Regulatory Pathway
- The pace at which Levicept advances LEVI-04 into Phase III trials and potential regulatory approval.
- Market Opportunity
- How LEVI-04’s differentiated mechanism of action will impact the $10B+ osteoarthritis drug market.
Related topics